novo nordisk patent semaglutide Ozempic's problem: how lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Novo Nordisk's Semaglutide Patent Expires

In an embryofetal development study in pregnant rabbits, subcutaneous doses of 0.0010, 0.0025 or 0.0075 mg/kg/day (0.03-, 0.3-, and 2.3-fold the MRHD) were administered throughout organogenesis from Gestation Day 6 to 19

Mitophagy contributes to this tumor-suppressive function by maintaining mitochondrial quality control (MQC)

Visit novonordisk-us.com/novocare or call 1-833-668-6463

But theres no need to panic

Mechanistic Incretin/Glucagon Research: Used to isolate the contributions of each receptor in appetite regulation, insulin sensitivity, lipid handling, and whole-body energy regulation

Be honest about this history even if it feels uncomfortable